Ulcerative Colitis
Conditions
Brief summary
Follow-Up Study with Retarded Release Phosphatidylcholine in Ulcerative Colitis Objectives: The objective of the study is to evaluate the follow up of patients treated with retarded release phosphatidylcholine in three controlled, randomized studies. Main question is to investigate whether treatment with phosphatidylcholine could spare patients the intake of steroids and immunosuppressants without clinical deterioration. Study population: * Retarded release phosphatidylcholine in chronic-active ulcerative colitis. * Retarded release phosphatidylcholine in steroid dependent ulcerative colitis. * Dose finding study for retarded release phosphatidylcholine Outcome parameters: Definition of remission: 1. SCCAI \<2,5 2. Likert scale: grade 1 or 2 3. subjective impression of remission: yes/no 4. no blood in stool Definition of relapse: 1. subjective impression: yes/no 2. SCCAI ≥ 5 3. blood in stool Definition of low clinical activity: SCCAI \< 5 Primary endpoint: sparing effect of steroids and/or immunosuppressants by rPC in chronic active UC. Secondary endpoints 1. maintenance of continuous remission 2. improvement of disease activity: a. clinical activity (SCCAI) b.life quality (SIBDQ-D) c.Likert Score 3. relapse rate: a. time to first relapse b. clinical activity during relapses c. number of relapses in relation to length of treatment
Interventions
2g phosphatidylcholine, given QTD
Sponsors
Heidelberg University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients from previous studies with retarded release phosphatidylcholine
Exclusion criteria
* patients with less then 6 weeks follow-up after end of initial study
Countries
Germany
Outcome results
None listed